VEA
SPRY icon

Virtus ETF Advisers’s ARS Pharmaceuticals SPRY Stock Holding History

Virtus ETF Advisers’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,371
Closed -$64K – 395
2021
Q3 		$64K Sell
6,371
-330
-5% -$8.14K 0.03% 392
2021
Q2 		$207K Buy
+6,701
New +$215K 0.09% 322

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Virtus ETF Advisers's SPRY Position: Q4 2021 in Review

Virtus ETF Advisers sold out of ARS Pharmaceuticals (SPRY) in Q4 2021, closing a stake of 6,371 shares — an estimated $64K sold.

Virtus ETF Advisers first reported a position in SPRY in Q2 2021 and held it in 2 quarters. The position peaked at $207K in Q2 2021. 72 funds tracked by Wall St. Rank hold SPRY as of Q4 2021.

  • Virtus ETF Advisers reported no remaining ARS Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 6,371 ARS Pharmaceuticals shares in Q4 2021, an estimated $64K.
  • Virtus ETF Advisers first reported a position in ARS Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Virtus ETF Advisers's ARS Pharmaceuticals position peaked at $207K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.